Integra Lifesciences Holdings (IART) Accumulated Expenses (2009 - 2026)

Integra Lifesciences Holdings' Accumulated Expenses history runs 18 years deep, the most recent figure standing at $133.3 million for Q1 2026.

• In Q1 2026, Accumulated Expenses rose 154.51% year-over-year to $133.3 million; the TTM figure through Mar 2026 stood at $133.3 million (up 154.51% YoY), while the FY2025 annual figure was $130.5 million, up 7.04% from the prior year.
• Accumulated Expenses came in at $133.3 million for Q1 2026 at Integra Lifesciences Holdings, up from $130.5 million in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $133.3 million in Q1 2026 to a low of $52.4 million in Q1 2025.
• A 5-year average of $92.3 million and a median of $93.4 million in 2023 frame the typical range for Accumulated Expenses.
• Across the five-year window, Accumulated Expenses sank 43.68% in 2024 and jumped 154.51% in 2026, its largest moves.
• Integra Lifesciences Holdings' Accumulated Expenses stood at $80.0 million in 2022, then gained by 26.0% to $100.8 million in 2023, then advanced by 20.89% to $121.9 million in 2024, then climbed by 7.04% to $130.5 million in 2025, then rose by 2.16% to $133.3 million in 2026.
• According to Business Quant data, Accumulated Expenses over the past three periods registered $133.3 million, $130.5 million, and $75.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison